找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Virus Entry Inhibitors; Stopping the Enemy a Shibo Jiang,Lu Lu Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive l

[復(fù)制鏈接]
樓主: ACRO
41#
發(fā)表于 2025-3-28 16:50:19 | 只看該作者
Human Papillomavirus (HPV) Entry Inhibitors,eveloping new diagnostic and prognostic biomarkers and designing more effective targeted therapeutics and treatment strategies remains urgent. Numerous efforts have been made to design new drugs and vaccines to treat HPV infections. Due to the special HPV infection pathway, entry inhibitors to block
42#
發(fā)表于 2025-3-28 21:22:27 | 只看該作者
43#
發(fā)表于 2025-3-29 00:42:34 | 只看該作者
44#
發(fā)表于 2025-3-29 04:59:27 | 只看該作者
Endogenous Peptide Inhibitors of HIV Entry,ents and beyond. Finally, we provide examples for other endogenous peptides that may contribute to our innate immune defense against HIV-1 and other viral pathogens and offer prospects for preventive or therapeutic development.
45#
發(fā)表于 2025-3-29 08:17:59 | 只看該作者
Virus Entry Inhibitors: Past, Present, and Future,e prophylaxis, microbicides, and therapeutics. This chapter, as well as this book, provides more information on the development and modification of peptide-, small-molecule-, and protein-based virus entry inhibitors.
46#
發(fā)表于 2025-3-29 13:03:34 | 只看該作者
47#
發(fā)表于 2025-3-29 17:37:41 | 只看該作者
Coronavirus Entry Inhibitors,ses in viral entry, such as receptor binding, proteolytic activation of spike protein, or virus-cell membrane fusion. Coronavirus entry inhibitors, alone or in combination with other drugs, play important roles in the treatment of coronavirus diseases. Thus, we summarize and discuss the development of coronavirus entry inhibitors in this chapter.
48#
發(fā)表于 2025-3-29 19:49:19 | 只看該作者
Influenza Virus Entry inhibitors,trials, including small molecule, natural product, peptide-based entry inhibitors, and other types of entry inhibitors, herein discussing some open questions. Assay methods of influenza virus entry inhibitors are also outlined.
49#
發(fā)表于 2025-3-30 02:32:43 | 只看該作者
50#
發(fā)表于 2025-3-30 04:48:46 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-16 07:50
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
铜山县| 晴隆县| 长白| 牡丹江市| 会宁县| 桦南县| 方正县| 巴里| 西宁市| 麻栗坡县| 城固县| 桓台县| 台中县| 仁寿县| 仪征市| 府谷县| 荣成市| 巫山县| 军事| 叶城县| 珠海市| 台湾省| 利川市| 拜泉县| 麻江县| 喀什市| 连平县| 武定县| 秦皇岛市| 岢岚县| 宜城市| 德格县| 瑞丽市| 于田县| 永德县| 奎屯市| 翼城县| 石家庄市| 西安市| 克拉玛依市| 无极县|